The neuromuscular manifestations of amyloidosis

Journal of Clinical Neuromuscular Disease

Volumn 11, Issue 3, 2010, Pages 145-157

  Simmons, Zachary ^a   Specht, Charles S ^a,b  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Amyloidosis; Myopathy; Peripheral neuropathy

Indexed keywords

GELSOLIN;

AMYLOIDOSIS; ELECTRODIAGNOSIS; GENETIC ANALYSIS; HUMAN; IMMUNOHISTOCHEMISTRY; LABORATORY TEST; LIVER TRANSPLANTATION; NEUROMUSCULAR DISEASE; PRIORITY JOURNAL; REVIEW;

AMYLOIDOSIS; APOLIPOPROTEIN A-I; ELECTROCARDIOGRAPHY; GELSOLIN; HUMANS; MUTATION; NEUROMUSCULAR DISEASES; PERIPHERAL NERVES; PREALBUMIN;

EID: 77949428192     PISSN: 15220443     EISSN: 15371611     Source Type: Journal    
DOI: 10.1097/CND.0b013e3181d05994     Document Type: Review

References (92)

1. Kyle RA, Kelly JJ, Dyck PJ. Amyloidosis and neuropathy. In: Dyck PJ, Thomas PK, eds. Peripheral Neuropathy, 4th ed. Philadelphia: Elsevier Saunders; 2005:2427-2451.
2. Eriksson M, Schonland S, Yumlu S, et al. Hereditary apolipoprotein AI-associated amyloidosis in surgical pathology specimens. J Mol Diagn. 2009;11:257-262.
3. Westermark P. Aspects on human amyloid forms and their fibril polypeptides. FEBS J. 2005;272:5942-5949.
4. Hawkins PN. Diagnosis and treatment of amyloidosis. Ann Rheum Dis. 1997;56:631-633.
5. Sipe JD, Cohen AS. Amyloidosis. In: Kasper DL, Braunwald E, Fauci AS, et al, eds. Harrison's Principles of Internal Medicine, 16th ed. New York: McGraw-Hill; 2005:2024-2029.
6. Kyle RA, Linos A, Beard CM, et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood. 1992;79:1817-1822.
7. Perfetti V, Colli Vignarelli M, Anesi E, et al. The degrees of plasma cell clonality and marrow infiltration adversely influence the prognosis of AL amyloidosis patients. Haematologica. 1999;84:218-221.
8. Hoffman J, Jhanwar S, Comenzo RL. AL amyloidosis and progression to multiple myeloma with gain(1q). Br J Haematol. 2008;144:963-964.
9. Kyle RA, Gertz MA. Systemic amyloidosis. Crit Rev Oncol Hematol. 1990;10:49-87.
10. Li K, Kyle RA, Dyck PJ. Immunohistochemical characterization of amyloid proteins in sural nerves and clinical associations in amyloid neuropathy. Am J Pathol. 1992;141:217-226.
11. Rajkumar SV, Gertz MA, Kyle RA. Prognosis of patients with primary systemic amyloidosis who present with dominant neuropathy. Am J Med. 1998; 104:232-237.
12. Kelly JJ. The electrodiagnostic findings in peripheral neuropathy associated with monoclonal gammopathy. Muscle Nerve. 1983;6:504-509.
13. Vital C, Vital A, Bouillot-Eimer S, et al. Amyloid neuropathy: a retrospective study of 35 peripheral nerve biopsies. J Peripher Nerv Syst. 2004;9:232-241.
14. Wechalekar AD, Hawkins PN, Gillmore JD. Perspectives in treatment of AL amyloidosis. Br J Haematol. 2008;140:365-377.
15. Merlini, G, Stone MJ. Dangerous small B-cell clones. Blood. 2006;108:2520-2530.
16. Dispenzieri A, Lacy MQ, Kyle RA, et al. Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. J Clin Oncol. 2001;19:3350-3356.
17. Benson MD, Kincaid JC. The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve. 2007;36:411-423.
18. Andrade C. A peculiar form of peripheral neuropathy: familiar atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain. 1952; 75:408-427.
19. Andersson R. Familial amyloidosis with polyneuropathy. Acta Med Scand. 1970;188:85-94.
20. Andersson R. Familial amyloidosis with polyneuropathy: a clinical study based on patients living in northern Sweden. Acta Med Scand Suppl. 1976;590: 1-64.
21. Araki S, Mawatari S, Ohta M, et al. Polyneurotic amyloidosis in a Japanese family. Arch Neurol. 1968; 18:593-602.
22. Tawara S, Araki S, Toshimori K, et al. Amyloid fibril protein in type I familial amyloidotic polyneuropathy in Japanese. J Lab Clin Med. 1981;98:811-822.
23. Costa PP, Figueira A, Bravo F. Amyloid fibril protein related to prealbumin in familial amyloidotic polyneuropathy. Proc Natl Acad Sci USA. 1978;75:4499-4503.
24. Hund E, Linke RP, Willig F, et al. Transthyretinassociated neuropathic amyloidosis: pathogenesis and treatment. Neurology. 2001;56:431-435.
25. Nakazato M. Genotype-phenotype relationship in familial amyloid polyneuropathy. Neurol Med Chir (Tokyo). 1998;48:528-534.
26. Misu K, Hattori N, Nagamatsu M. Late-onset familial amyloid polyneuropathy type I (transthyretin Met30- associated familial amyloid polyneuropathy) unrelated to endemic focus in Japan. Clinicopathological and genetic features. Brain. 1999;122:1951-1962.
27. Ikeda S, Nakazato M, Ando Y, et al. Familial transthyretin-type amyloid polyneuropathy in Japan: clinical and genetic heterogeneity. Neurology. 2002; 58:1001-1007.
28. Sousa A, Andersson R, Drugge U, et al. Familial amyloidotic polyneuropathy in Sweden: geographical distribution, age of onset, and prevalence. Hum Hered. 1993;43:288-294.
29. Plante-Bordeneuve V, Lalu T, Misrahi M, et al. Genotypic-phenotypic variations in a series of 65 patients with familial amyloid polyneuropathy. Neurology. 1998;51:708-714.
30. Sousa A, Coelho T, Lobato L, et al. Genetic epidemiology of familial amyloidotic polyneuropathy (FAP)-type I in Povoa do Varzim and Vila do Conde (North of Portugal). Am J Med Genet. 1995;60: 512-521.
31. Sequeiros J, Saraiva MJ. Onset in the seventh decade and lack of symptoms in heterozygotes for the TTR met30 mutation in hereditary amyloid neuropathytype I (Portuguese, Andrade). Am J Med Genet. 1987;27:345-357.
32. Nakazato M, Tanaka M, Yamamura Y, et al. Abnormal transthyretin in asymptomatic relatives in familial amyloidotic polyneuropathy. Arch Neurol. 1987;44: 1275-1278.
33. Coelho T, Sousa A, Lourenco E, et al. A study of 159 Portuguese patients with familial amyloidotic polyneuropathy (FAP) whose parents were both unaffected. J Med Genet. 1994;31:293-299.
34. Reilly MM, Adams D, Booth DR, et al. Transthyretin gene analysis in European patients with suspected familial amyloid polyneuropathy. Brain. 1995;118: 849-856.
35. Munar-Qués M, Pedrosa JL, Coelho T, et al. Two pairs of proven monozygotic twins discordant for familial amyloid polyneuropathy (FAP) TTR Met 30. J Med Genet. 1999;36:629-632.
36. Soares ML, Coelho T, Sousa A, et al. Susceptibility and modifier genes in Portuguese transthyretin V30M amyloid polyneuropathy: complexity in a single-gene disease. Hum Mol Genet. 2005;14: 543-553.
37. Kawaji T, Ando Y, Ando E, et al. A case of vitreous amyloidosis without systemic symptoms in familial amyloidotic polyneuropathy. Amyloid. 2004;11: 257-259.
38. Brett M, Persey MR, Reilly MM, et al. Transthyretin Leu12Pro is associated with systemic, neuropathic and leptomeningeal amyloidosis. Brain. 1999;122: 183-190.
39. Uemichi T, Uitti RJ, Koeppen AH, et al. Oculoleptomeningeal amyloidosis associated with a new transthyretin variant Ser64. Arch Neurol. 1999;56: 1152-1155.
40. Ellie E, Camou F, Vital A, et al. Recurrent subarachnoid hemorrhage associated with a new transthyretin variant (Gly53Glu). Neurology. 2001;57: 135-137.
41. Blevins G, Maccaulay R, Harder S, et al. Oculoleptomeningeal amyloidosis in a large kindred with a new transtryretin variant Tyr69His. Neurology. 2003;60: 1625-1630.
42. Van Allen MW, Frohlich JA, Davis JR. Inherited predisposition to generalized amyloidosis. Clinical and pathological study of a family with neuropathy, nephropathy, and peptic ulcer. Neurology. 1969;19: 10-25.
43. Gillmore JD, Stangou AJ, Lachmann HJ, et al. Organ transplantation in hereditary apolipoprotein AI amyloidosis. Am J Transplant. 2006;6:2342-2347.
44. Nichols WC, Gregg RE, Brewer HB, et al. A mutation in apolipoprotein A-I in the Iowa type of familial amyloidotic polyneuropathy. Genomics. 1990;8: 318-323.
45. Ghiso J, Haltia M, Prelli F, et al. Gelsolin variant (Asn- 187) in familial amyloidosis, Finnish type. Biochem J. 1990;272:827-830.
46. Levy E, Haltia M, Fernandez-Madrid I, et al. Mutation in gelsolin gene in Finnish hereditary amyloidosis. J Exp Med. 1990;172:1865-1867.
47. De La Chapelle A, Tolvanen R, Boysen G, et al. Gelsolin-derived familial amyloidosis caused by asparagine or tyrosine substitution for aspartic acid at residue 187. Nat Genet. 1992;2:157-160.
48. Meretoja J. Familial systemic paramyloidosis with lattice dystrophy of the cornea, progressive cranial neuropathy, skin changes and various internal symptoms. Ann Clin Res. 1969;1:314-324.
49. Meretoja J. Genetic aspects of familial amyloidosis with corneal lattice dystrophy and cranial neuropathy. Clin Genet. 1973;4:173-185.
50. Kiuru S. Familial amyloidosis of the Finnish type (FAF): a clinical study of 30 patients. Acta Neurol Scand. 1992;86:346-353.
51. Boysen G, Galassi G, Kamieniecka Z, et al. Familial amyloidosis with cranial neuropathy and corneal lattice dystrophy. J Neurol Neurosurg Psychiatry. 1979;42:1020-1030.
52. Darras BT, Adelman LS, Mora JS, et al. Familial amyloidosis with cranial neuropathy and corneal lattice dystrophy. Neurology. 1986;36:432-435.
53. Gorevic PD, Munoz PC, Gorgone G, et al. Amyloidosis due to a mutation of the gelsolin gene in an American family with lattice corneal dystrophy type II. N Engl J Med. 1991;325:1780-1785.
54. Makishita H, Yazaki M, Matsuda M, et al. Familial amyloid polyneuropathy type IV (Finnish-type). A clinicopathological study. Rinsho Shinkeigaku. 1994;34:431-437.
55. Akiya S, Nishio Y, Ibi K, et al. Lattice corneal dystrophy type II associated with familial amyloid polyneuropathy type IV. Ophthalmology. 1996;103: 1106-1110.
56. Kiuru S. Gelsolin-related familial amyloidosis, Finnish type (FAF) and its variants found worldwide. A review. Amyloid. 1998;5:55-66.
57. Stewart HS, Parveen R, Ridgway AE, et al. Late onset lattice corneal dystrophy with systemic familial amyloidosis, amyloidosis V, in an English family. Br J Ophtalmol. 2000;84:390-394.
58. Conceiccao I, Sales-Luis ML, De Carvalho M, et al. Gelsolin-related familial amyloidosis, Finnish type, in a Portuguese family: clinical and neurophysiological studies. Muscle Nerve. 2003;28:715-721.
59. Hornigold R, Patel AV, Ward VMM, et al. Familial systemic amyloidosis associated with bilateral sensorineural hearing loss and bilateral facial palsies. J Laryngol Otol. 2006;120:778-780.
60. Kiuru S, Seppalainen A-M. Neuropathy in familial amyloidosis, Finnish type (FAF): electrophysiological studies. Muscle Nerve. 1994;17:299-304.
61. Tanskanen M, Paetau A, Salonen O, et al. Severe ataxia with neuropathy in hereditary gelsolin amyloidosis: a case report. Amyloid. 2007;14:89-95.
62. Kiuru S, Matikainen E, Kupari M, et al. Autonomic nervous system and cardiac involvement in familial amyloidosis, Finnish type (FAF). J Neurol Sci. 1994; 126:40-48.
63. Chastan N, Baert-Desurmont S, Saugier-Veber P, et al. Cardiac conduction alterations in a French family with amyloidosis of the Finnish type with the p. Asp187Tyrmutation in the GSN gene. Muscle Nerve. 2005;33:113-119.
64. Kiuru S, Salonen O, Haltia M. Gelsolin-related spinal and cerebral amyloid angiopathy. Ann Neurol. 1999; 45:305-311.
65. Sales Luis ML. Electroneurophysiological studies in familial amyloid polyneuropathy-Portuguese type. J Neurol Neurosurg Psychiatry. 1978;41:847-850.
66. Dyck PJ, Lambert EH. Dissociated sensation in amyloidosis: compound action potential, quantitative histologic and teased-fiber, and electron microscopic studies of sural nerve biopsies. Arch Neurol. 1969; 20:490-507.
67. Kiuru-Enari S, Somer H, Seppalainen A-M, et al. Neuromuscular pathology in hereditary gelsolin amyloidosis. J Neuropathol Exp Neurol. 2002;61: 565-571.
68. Shimojima Y, Morita H, Kobayashi S, et al. Ten-year followup of peripheral nerve function in patients with familial amyloid polyneuropathy after liver transplantation. J Neurol. 2008;255:1220-1225.
69. Ikeda S, Hanyu N, Hongo M, et al. Hereditary generalized amyloidosis with polyneuropathy. Clinicopathological study of 65 Japanese patients. Brain. 1987;110:315-337.
70. Holmgren G, Steen L, Ekstedt J, et al. Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30). Clin Genet. 1991;40:242-246.
71. The Familial Amyloidotic Polyneuorpathy World Transplant Registry.Available at: http://www.fapw tr.org. Accessed December 1, 2009.
72. Matsunami H, Makuuchi M, Kawasaki S, et al. A case of familial amyloid polyneuropathy treated with partial liver transplantation using a graft from a living related donor. Transplantation. 1995;60:301-303.
73. Tashima K, Ando Y, Terazaki H, et al. Outcome of liver transplantation for transthyretin amyloidosis: follow-up of Japanese familial amyloidotic polyneuropathy patients. J Neurol Sci. 1999 171:19-23.
74. Adams D, Samuel D, Goulon-Goeau C, et al. The course and prognostic factors of familial amyloid polyneuropathy after liver transplantation. Brain. 2000;123:1495-1504.
75. De Carvalho M, Conceicao I, Bentes C, et al. Longterm quantitative evaluation of liver transplantation in familial amyloid polyneuropathy (Portuguese V30M). Amyloid. 2002;9:126-133.
76. Kobayashi S, Morita H, Asawa T, et al. Peripheral nerve function in patients with familial amyloid polyneuropathy after liver transplantation. Amyloid. 2003;10:17-24.
77. Calandra S, Tarugi P. Synthesis and secretion of apolipoprotein A-I. Biochem Soc Trans. 1993;21:493.
78. Gillmore JD, Stangou AJ, Tennent GA, et al. Clinical and biochemical outcome of hepatorenal transplantation for hereditary systemic amyloidosis associated with apoliprotein AI Gly26Arg. Transplantation. 2001;71:986-992.
79. Testro AG, Brennan SO, Macdonnell RAL, et al. Hereditary amyloidosis with progressive peripheral neuropathy associated with apolipoprotein AI Gly26Arg: outcome of hepatorenal transplantation. Liver Transpl. 2007;13:1028-1031.
80. Kelly JJ. Peripheral neuropathies associated with monoclonal proteins: a clinical review. Muscle Nerve. 1985;8:138-150.
81. Simmons Z, Blaivs M, Aguilera AJ, et al. Low diagnostic yield of sural nerve biopsy in patients with peripheral neuropathy and primary amyloidosis. J Neurol Sci. 1993;120:60-63.
82. Verghese JP, Bradley WG, Nemni R, et al. Amyloid neuropathy in multiple myeloma and other plasma cell dyscrasias: a hypothesis of the pathogenesis of amyloid neuropathies. J Neurol Sci. 1983;59: 237-246.
83. Hanyu N, Ikeda S, Nakadai A, et al. Peripheral nerve pathologic findings in familial amyloid polyneuropathy: a correlative study of proximal sciatic nerve and sural nerve lesions. Ann Neurol. 1989;25:340-350.
84. Antoine JC, Baril A, Guettier C, et al. Unusual amyloid polyneuropathy with predominant lumbosacral nerve roots and plexus involvement. Neurology. 1991;41:206-208.
85. Whitaker JN, Hashimoto K, Quinones M. Skeletal muscle pseudohypertrophy in primary amyloidosis. Neurology. 1977;27:47-54.
86. Elomaa I, Ekblom P, Somer T. Amyloid-associated muscle pseudohypertrophy and multiple myeloma in a man with hypernephroma. Acta Med Scand. 1983;214: 87-91.
87. Yamada M, Tsukagoshi H, Hatakeyama S. Skeletal muscle amyloid deposition in AL- (primary or myeloma-associated), AA- (secondary), and prealbumin- type amyloidosis. J Neurol Sci. 1988;85:223-232.
88. Gertz MA, Kyle RA. Myopathy in primary systemic amyloidosis. J Neurol Neurosurg Psychiatry. 1996; 60:655-660.
89. Sibelt LAG, Lokhorst HM, Van De Kerkhof PCM, et al. J Eur Acad Dermatol Venereol. 2007;21:986-988.
90. Streeten EA, De La Monte SM, Kennedy TP. Amyloid infiltration of the diaphragm as a cause of respiratory failure. Chest. 1986;89:760-762.
91. Santiago RM, Scharnhorst D, Ratkin G, et al. Respiratory muscle weakness and ventilatory failure in AL amyloidosis with muscular pseudohypertrophy. Am J Med. 1987;83:175-178.
92. Ashe J, Borel CO, Hart G, et al. Amyloid myopathy presenting with respiratory failure. J Neurol Neurosurg Psychiatry. 1992;55:162-165.